Should I buy or sell Bicycle Therapeutics stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCYC shares. View BCYC analyst ratings or view top-rated stocks .

What is Bicycle Therapeutics' stock price target for 2024?

7 Wall Street research analysts have issued 1-year target prices for Bicycle Therapeutics' shares. Their BCYC share price targets range from $32.00 to $65.00. On average, they predict the company's share price to reach $46.86 in the next twelve months. This suggests a possible upside of 99.8% from the stock's current price. View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts .

How have BCYC shares performed in 2024?

Bicycle Therapeutics' stock was trading at $18.08 at the beginning of 2024. Since then, BCYC stock has increased by 29.7% and is now trading at $23.45. View the best growth stocks for 2024 here .

When is Bicycle Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024. View our BCYC earnings forecast .

How were Bicycle Therapeutics' earnings last quarter?

Bicycle Therapeutics plc (NASDAQ:BCYC) released its earnings results on Tuesday, February, 20th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.07. The company had revenue of $5.33 million for the quarter, compared to the consensus estimate of $11.68 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 57.80% and a negative net margin of 669.72%.

What ETFs hold Bicycle Therapeutics' stock?

ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX) , Range Cancer Therapeutics ETF (CNCR) , Loncar China Biopharma ETF (CHNA) , Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Harbor Health Care ETF (MEDI) . Harbor Disruptive Innovation ETF (INNO) .

What other stocks do shareholders of Bicycle Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX) , AVEO Pharmaceuticals (AVEO) , Fulcrum Therapeutics (FULC) , Mersana Therapeutics (MRSN) , AbbVie (ABBV) , Adverum Biotechnologies (ADVM) , Agenus (AGEN) , Applied Genetic Technologies (AGTC) , Akero Therapeutics (AKRO) and Alector (ALEC) .

When did Bicycle Therapeutics IPO?

Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.

Who are Bicycle Therapeutics' major shareholders?

Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Woodstock Corp (0.08%). Insiders that own company stock include Alistair Milnes, Kate Bingham , Kevin Lee , Lee Kalowski , Michael Charles Ferguso Hannay, Michael Skynner, Nicholas Keen , Nigel Crockett , Pierre Legault , Stephen B Alexander and Travis Alvin Thompson. View institutional ownership trends .

How do I buy shares of Bicycle Therapeutics?

Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here .

NASDAQ:BCYC

Bicycle Therapeutics (BCYC) Stock Price, News & Analysis

→ The Best AI Stock to Own in the World Today is Trading for Just $25 (From Banyan Hill Publishing) (Ad)

Free BCYC Stock Alerts

$23.45

-1.04 (-4.25%)

(As of 04/19/2024 ET)

Compare

Today's Range: $23.06
▼
$24.61
50-Day Range: $17.42
▼
$26.10
52-Week Range: $12.54
▼
$28.91

Volume: 546,482 shs
Average Volume: 382,602 shs
Market Capitalization: $704.44 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $46.86

Get Bicycle Therapeutics alerts:

Bicycle Therapeutics MarketRank™ Stock Analysis

Analyst Rating: Moderate Buy
2.86 Rating Score
Upside/Downside: 99.8% Upside
$46.86 Price Target
Short Interest: Bearish
8.46% of Shares Sold Short
Dividend Strength: N/A
Sustainability: N/A
News Sentiment: 0.35
Based on 6 Articles This Week
Insider Trading: Selling Shares
$126,139 Sold Last Quarter
Proj. Earnings Growth: Decreasing
From ($5.20) to ($5.82) Per Share

Overall MarketRank^™

New Rank-Based ScoringMarketRank^™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

1.99 out of 5 stars

Medical Sector

571st out of 911 stocks

Pharmaceutical Preparations Industry

253rd out of 410 stocks

3.4

Analyst's Opinion

Consensus Rating
Bicycle Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.86, and is based on 6 buy ratings, 1 hold rating, and no sell ratings.
Amount of Analyst Coverage
Bicycle Therapeutics has only been the subject of 3 research reports in the past 90 days.

2.0

Short Interest

Percentage of Shares Shorted
8.46% of the outstanding shares of Bicycle Therapeutics have been sold short.
Short Interest Ratio / Days to Cover
Bicycle Therapeutics has a short interest ratio ("days to cover") of 6.6.
Change versus previous month
Short interest in Bicycle Therapeutics has recently decreased by 0.78%, indicating that investor sentiment is improving.

0.0

Dividend Strength

Dividend Yield
Bicycle Therapeutics does not currently pay a dividend.
Dividend Growth
Bicycle Therapeutics does not have a long track record of dividend growth.

N/A

Sustainability and ESG

Overall ESG (Environmental, Social, and Governance) Score
There is no current Upright™ data available for BCYC.

2.4

News and Social Media Coverage

News Sentiment
Bicycle Therapeutics has a news sentiment score of 0.35. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.52 average news sentiment score of Medical companies.
News Coverage This Week
MarketBeat has tracked 6 news articles for Bicycle Therapeutics this week, compared to 4 articles on an average week.
Search Interest
5 people have searched for BCYC on MarketBeat in the last 30 days. This is an increase of 400% compared to the previous 30 days.

3.3

Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Bicycle Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $126,139.00 in company stock.
Percentage Held by Insiders
10.20% of the stock of Bicycle Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.
Percentage Held by Institutions
86.15% of the stock of Bicycle Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.0

Earnings and Valuation

Earnings Growth
Earnings for Bicycle Therapeutics are expected to decrease in the coming year, from ($5.20) to ($5.82) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Bicycle Therapeutics is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Bicycle Therapeutics is -4.57, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Bicycle Therapeutics has a P/B Ratio of 1.90. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Ad Paradigm Press

Bitcoin Rockets To Record High But Buy THIS Instead

Recently, Bitcoin smashed through its previous record high to hit $72,720. It’s made many, many people very rich. But one cryptocurrency expert and investing millionaire is declaring…

>>Click here to find out what it is.

About Bicycle Therapeutics Stock (NASDAQ:BCYC)

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial. The company also developing BT1718, a bicycle toxin conjugate (BTC), which is in Phase I/IIa clinical trials targeting tumors that express Membrane Type 1 matrix metalloprotease; and BT7401, a multivalent bicycle CD137 agonist which is in phase IIa to treat advanced solid tumors. In addition, it develops Novel anti-infective, which is in preclinical trial targeting anti-infectives disease; CNS targets, which is in preclinical trial targeting CNS disease; and Novel neuromuscular targets, which is in preclinical trial targeting neuromuscular disease. Further, the company collaborates with biopharmaceutical companies and organizations to develop programs in therapeutic areas. It has collaboration and license agreement with Bayer Consumer Care AG; Novartis Pharma AG; Cancer Research UK; Cancer Research Technology Ltd; and Oxurion NV. Bicycle Therapeutics plc was incorporated in 2009 and is headquartered in Cambridge, the United Kingdom.

BCYC Stock Price History

30 days | 90 days | 365 days | Advanced Chart

BCYC Stock News Headlines

April 7, 2024 | insidertrades.com

Nicholas Keen Sells 790 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC) Stock

April 20, 2024 | americanbankingnews.com

Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up to $21.82

April 20, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

Many have already secured their free Bitcoin reward offered by our esteemed guest. How about you? In an effort to spread the word about our upcoming workshop, he's generously offering $10 in Bitcoin (BTC) to participants. Absolutely no strings attached.

April 19, 2024 | forbes.com

The Bicycle Day Dream Bike: A Carbon Fiber Hommage To Albert Hofmann

April 18, 2024 | msn.com

NCDOT Bicycle Helmet Initiative to begin soon

April 18, 2024 | yahoo.com

Lebanon Bicycle Recycle gears up annual Spring Fling hoping to give away 100 bikes to kids

April 14, 2024 | investing.com

Bicycle therapeutics executive sells shares to cover tax withholding obligations

April 12, 2024 | msn.com

The Bicycle Bakery in Camden Road, Tunbridge Wells closes after owner opens up about health problems but hopes to reopen in summer

April 20, 2024 | Crypto Swap Profits (Ad)

Claim Your Complimentary Bitcoin Reward

April 12, 2024 | msn.com

38th annual Redlands Bicycle Classic kicks off with women's division making strides in the sport

April 11, 2024 | msn.com

‘Bicycle nazis’: Winnipeg city councillor taking heat after committee meeting comment

April 11, 2024 | msn.com

The Bicycle Bakery: Award-winning Tunbridge Wells bakery that had queues down the street to close

April 11, 2024 | americanbankingnews.com

Bicycle Therapeutics' (BCYC) Buy Rating Reiterated at Needham & Company LLC

April 10, 2024 | americanbankingnews.com

Bicycle Therapeutics plc (NASDAQ:BCYC) Receives Average Rating of "Moderate Buy" from Analysts

April 9, 2024 | msn.com

LA Once Had A Bicycle Freeway. What Happened To 1900's Cyclist Dream?

April 9, 2024 | markets.businessinsider.com

Bicycle Therapeutics: Strong Buy on Breakthrough Preclinical Data, Clinical Progress, and Robust Financial Health

April 7, 2024 | investing.com

Bicycle therapeutics executive sells shares worth over $3,600

April 6, 2024 | ca.news.yahoo.com

Peterborough Bicycle Advisory Committee gets in gear for spring cycling summit

April 4, 2024 | usnews.com

Gaza's Wasteland Seen Via Bicycle After Six Months of War

April 2, 2024 | finance.yahoo.com

Bicycle Therapeutics to Participate in the 23rd Annual Needham Virtual Healthcare Conference

March 27, 2024 | msn.com

Trek’s New Wahoo Path Hybrid Kids Line Helps Create Life-Long Bicycle Riders

March 21, 2024 | bizjournals.com

Red Bicycle coffee shop in The Nations temporarily closed due to fire damage

March 19, 2024 | msn.com

Take a cool bike ride at Icicle Bicycle

March 17, 2024 | msn.com

Trek Bicycle in Little Rock holds grand reopening after March 31 tornado destroyed original location

March 16, 2024 | msn.com

Riverbend Bicycle Club, Clinton, hosts annual ride

March 16, 2024 | finance.yahoo.com

BCYC Apr 2024 12.500 call

March 16, 2024 | finance.yahoo.com

BCYC Apr 2024 22.500 call

See More Headlines

Receive BCYC Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Bicycle Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings: 2/20/2024
Today: 4/20/2024
Next Earnings (Estimated): 5/02/2024
Fiscal Year End: 12/31/2024

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Sector: Medical
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Current Symbol: NASDAQ:BCYC
CUSIP: N/A
CIK: 1761612
Web: www.bicycletherapeutics.com
Phone: 441223261503
Fax: N/A
Employees: 284
Year Founded: N/A

Price Target and Rating

Average Stock Price Target: $46.86
High Stock Price Target: $65.00
Low Stock Price Target: $32.00
Potential Upside/Downside: +99.8%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.86
Research Coverage: 7 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($5.13)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-180,660,000.00
Net Margins: -669.72%
Pretax Margin: -664.32%
Return on Equity: -57.80%
Return on Assets: -34.14%

Debt

Debt-to-Equity Ratio: 0.08
Current Ratio: 8.08
Quick Ratio: 8.08

Sales & Book Value

Annual Sales: $26.98 million
Price / Sales: 26.11
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $12.35 per share
Price / Book: 1.90

Miscellaneous

Outstanding Shares: 30,040,000
Free Float: 26,979,000
Market Cap: $704.44 million
Optionable: Optionable
Beta: 0.89

These 7 Stocks Will Be Magnificent in 2024

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

Key Executives

Dr. Kevin Lee M.B.A. (Age 56)
Ph.D., CEO & Executive Director
Comp: $1.31M
Mr. Lee H. Kalowski M.B.A. (Age 43)
President
Comp: $879.99k
Sir Gregory Paul Winter CBE (Age 73)
FMedsci, FRS, HonFRCP, HonFTSE, Co-Founder & Non-Executive Director
Comp: $55k
Mr. Alistair Milnes (Age 50)
Chief Operating Officer
Comp: $796.09k
Dr. Michael Skynner B.sc. Ph.d. (Age 54)
Ph.D., Chief Technology Officer
Comp: $881.01k
Dr. Christian Heinis
Scientific Founder
Ms. Alethia Rene Young (Age 45)
Chief Financial Officer
Mr. Travis Thompson
Senior VP, Chief Accounting Officer & Principal Accounting Officer
Dr. Nicholas Keen Ph.D. (Age 55)
Chief Scientific Officer
Mr. Zafar Qadir
General Counsel

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

BCYC Stock Analysis - Frequently Asked Questions

Should I buy or sell Bicycle Therapeutics stock right now?: 7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Bicycle Therapeutics in the last year. There are currently 1 hold rating and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" BCYC shares.
View BCYC analyst ratings or view top-rated stocks.
What is Bicycle Therapeutics' stock price target for 2024?: 7 Wall Street research analysts have issued 1-year target prices for Bicycle Therapeutics' shares. Their BCYC share price targets range from $32.00 to $65.00. On average, they predict the company's share price to reach $46.86 in the next twelve months. This suggests a possible upside of 99.8% from the stock's current price.
View analysts price targets for BCYC or view top-rated stocks among Wall Street analysts.
How have BCYC shares performed in 2024?: Bicycle Therapeutics' stock was trading at $18.08 at the beginning of 2024. Since then, BCYC stock has increased by 29.7% and is now trading at $23.45.
View the best growth stocks for 2024 here.
When is Bicycle Therapeutics' next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, May 2nd 2024.
View our BCYC earnings forecast.
How were Bicycle Therapeutics' earnings last quarter?: Bicycle Therapeutics plc (NASDAQ:BCYC) released its earnings results on Tuesday, February, 20th. The company reported ($1.16) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($1.23) by $0.07. The company had revenue of $5.33 million for the quarter, compared to the consensus estimate of $11.68 million. Bicycle Therapeutics had a negative trailing twelve-month return on equity of 57.80% and a negative net margin of 669.72%.
What ETFs hold Bicycle Therapeutics' stock?: ETFs with the largest weight of Bicycle Therapeutics (NASDAQ:BCYC) stock in their portfolio include Horizon Kinetics Medical ETF (MEDX), Range Cancer Therapeutics ETF (CNCR), Loncar China Biopharma ETF (CHNA), Virtus LifeSci Biotech Clinical Trials ETF (BBC) and Harbor Health Care ETF (MEDI).Harbor Disruptive Innovation ETF (INNO).

What other stocks do shareholders of Bicycle Therapeutics own?: Based on aggregate information from My MarketBeat watchlists, some companies that other Bicycle Therapeutics investors own include Aldeyra Therapeutics (ALDX), AVEO Pharmaceuticals (AVEO), Fulcrum Therapeutics (FULC), Mersana Therapeutics (MRSN), AbbVie (ABBV), Adverum Biotechnologies (ADVM), Agenus (AGEN), Applied Genetic Technologies (AGTC), Akero Therapeutics (AKRO) and Alector (ALEC).
When did Bicycle Therapeutics IPO?: Bicycle Therapeutics (BCYC) raised $64 million in an initial public offering on Thursday, May 23rd 2019. The company issued 4,300,000 shares at $14.00-$16.00 per share. Goldman Sachs, Jefferies and Piper Jaffray acted as the underwriters for the IPO and Canaccord Genuity was co-manager.
Who are Bicycle Therapeutics' major shareholders?: Bicycle Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Woodstock Corp (0.08%). Insiders that own company stock include Alistair Milnes, Kate Bingham, Kevin Lee, Lee Kalowski, Michael Charles Ferguso Hannay, Michael Skynner, Nicholas Keen, Nigel Crockett, Pierre Legault, Stephen B Alexander and Travis Alvin Thompson.
View institutional ownership trends.
How do I buy shares of Bicycle Therapeutics?: Shares of BCYC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:BCYC) was last updated on 4/20/2024 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial